燃石医学的Oncoguide™ Oncoscreen™ Plus Cdx系统现已在日本正式获得监管批准,将作为乳腺癌治疗中Capivasertib药物的伴随诊断系统投入使用。
这一监管批准标志着燃石医学在日本精准医疗市场取得重要进展,其诊断系统将为乳腺癌患者的个性化治疗提供关键的检测支持。
燃石医学的Oncoguide™ Oncoscreen™ Plus Cdx系统现已在日本正式获得监管批准,将作为乳腺癌治疗中Capivasertib药物的伴随诊断系统投入使用。
这一监管批准标志着燃石医学在日本精准医疗市场取得重要进展,其诊断系统将为乳腺癌患者的个性化治疗提供关键的检测支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.